SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 12.63 |
Enterprise Value ($M) | -6.51 |
Book Value ($M) | 45.78 |
Book Value / Share | 1.82 |
Price / Book | 0.28 |
NCAV ($M) | 40.62 |
NCAV / Share | 1.62 |
Price / NCAV | 0.31 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.59 |
Return on Assets (ROA) | -0.36 |
Return on Equity (ROE) | -0.42 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 8.84 |
Current Ratio | 8.84 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 48.10 |
Assets | 53.25 |
Liabilities | 7.47 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | Newtyn Management, LLC | 4.95 | -14.72 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
116,251 | 411,146 | 28.27 | |
507,797 | 1,243,229 | 40.85 | |
184,256 | 588,076 | 31.33 | |
84,156 | 748,702 | 11.24 | |
(click for more detail) |
Similar Companies | |
---|---|
SIGA – SIGA Technologies, Inc. | SKYE – Skye Bioscience, Inc. |
SMMT – Summit Therapeutics Inc. | SNYR – Synergy CHC Corp. |
SPRY – ARS Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io